Enveric Biosciences Inc. (ENVB) News

Enveric Biosciences Inc. (ENVB): $1.77

-0.08 (-4.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ENVB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 509

in industry

Filter ENVB News Items

ENVB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ENVB News Highlights

  • ENVB's 30 day story count now stands at 6.
  • Over the past 28 days, the trend for ENVB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • BODY and CNS are the most mentioned tickers in articles about ENVB.

Latest ENVB News From Around the Web

Below are the latest news stories about Enveric Biosciences Inc that investors may wish to consider to help them evaluate ENVB as an investment opportunity.

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.

Yahoo | October 18, 2021

Enveric Biosciences on the Merger with MagicMed

By Exec Edge Editorial Staff Exec Edge: How did the merger between Enveric and MagicMed come about? ​​Enveric had been looking to complement their existing product development activities, which are focused on physical symptoms, with a platform of novel psychedelics that addresses the large mental health challenges related to CNS indications such as Cancer Related […]

Yahoo | October 15, 2021

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional investors, advisors, and analysts are invited to attend the two-day program beginning Wednesday, October 13, 2021, at 9:45 a.m. ET.

Yahoo | October 11, 2021

Enveric Biosciences to Participate in Upcoming Investor Conferences in October 2021

Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in two upcoming October conferences:

Yahoo | October 7, 2021

Enveric Biosciences Announces Artificial Intelligence Platform, PsyAI™, Has Identified Viable Drug Candidates from its 'Psybrary' of Psychedelic Molecular Compounds

Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that PsyAITM – an artificial intelligence tool designed by April19 to provide comprehensive pharmaceutical design, manufacturing, pharmacology predictive and validating methodologies – has successfully identified via

Yahoo | October 5, 2021

Enveric Biosciences to Participate in Upcoming Investor Conferences in September 2021

Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform for the mind and body using psychedelics and cannabinoids, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in two upcoming investor conferences:

Yahoo | September 20, 2021

Enveric Biosciences Announces Closing of MagicMed Industries Acquisition

Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the closing of its acquisition of MagicMed Industries Inc. ("MagicMed"), a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine (DMT) and other molecular derivatives with applications across mu

Yahoo | September 17, 2021

Enveric Biosciences Announces MagicMed Industries' Presentations at the Following Investor Conferences in September

Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that Dr. Joseph Tucker, MagicMed Industries' ("MagicMed") Chief Executive Officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference and Virtual Gravitas Health Reimagined Investor Day.

Yahoo | September 9, 2021

Enveric Biosciences CEO, David Johnson, Issues Letter to Shareholders

Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel therapeutic drugs to improve the quality of life for cancer patients, Chief Executive Officer, David Johnson, today is issuing an open letter to shareholders.

Yahoo | August 18, 2021

New CBD Trials Point the Way for Enveric, MagicMed

Whitefish, Montana--(Newsfile Corp. - August 2, 2021) - CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced an article covering Enveric Biosciences (NASDAQ: ENVB) and MagicMed Industries Inc.Enveric and MagicMedTo view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/6612/91804_4a0554a87440697c_001full.jpgAs the cannabis indust

Yahoo | August 2, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7528 seconds.